Android app on Google Play

Covidien (COV) Launches OneShot Renal Denervation System

January 16, 2013 7:01 AM EST Send to a Friend
Covidien (NYSE: COV) announced the commercial launch of the OneShotâ„¢ Renal Denervation System, an over the wire balloon-based irrigated catheter technology for the treatment of high blood pressure or hypertension.

Placed percutaneous, OneShot delivers radiofrequency (RF) energy in a circumferential manner to the renal arterial wall, and requires only a single treatment per artery. OneShot received the CE Mark in February 2012 and has been undergoing clinical trial evaluation in New Zealand and Europe. The product will be rolled out in Europe, Middle East, Africa, Asia and Latin America over the next several months.

Hypertension affects one billion people worldwide of all ages.1 It occurs when the force of blood pushing against the vessel walls is too high, which can damage the vessels and cause life-threatening conditions. Hypertension is a chronic condition that significantly increases the risk of stroke, heart attack, heart failure and kidney disease.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment